The study included 214 patients who had previously been infected with SARS-CoV-2. Clinical samples were collected at a mean of 44 days after the initial infection.

Google

To evaluate the performance of serological assays for SARS-CoV-2, 214 patients previously infected with the virus were tested using 5 different commercially available assays. The diagnostic accuracy of these assays was then compared using statistical measures.

Methods of Comparing Five SARS-CoV-2 Serologic Assays

Patel E, Bloch EM, Clarke W, et al. Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers. Preprint. medRxiv. 2020;2020.08.31.20184788. Published 2020 Sep 2. doi:10.1101/2020.08.31.20184788

Comparative performance of five commercially available serologic assays to detect antibodies to SARS-coV-2 and identify individuals with high neutralizing titers. 

Participant Cohort for SARS-CoV-2 Serologic Assay Comparison

The 5 serological assays evaluated include the Euroimmun Anti-SARS-CoV-2 ELISA, the Epitope Diagnostics, Inc. (EDI) Novel Coronavirus COVID-19 IgG ELISA Kit, the ImmunoDiagnostics SARS-CoV-2 NP IgG ELISA kit, the Abbott-Architect SARS-CoV-2 IgG CMIA, and the Roche Diagnostics Elecsys® Anti-SARS-CoV-2 E-CLIA.

Serological Assays Evaluated for SARS-CoV-2 Antibody Detection

AUROC values (the area underneath the receiver operating curve) were calculated from an empirical receiver operating curve to compare the diagnostic performance of the 5 serological assays.

Learn Before

Related